| 1 |
35092492 | Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells. | 2022 Jan 29 |
1 |
| 2 |
35164068 | 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion. | 2022 Jan 26 |
1 |
| 3 |
35256549 | Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia. | 2022 Mar 31 |
1 |
| 4 |
35402127 | Effective collaboration between hematologists and cardiologists facilitated successful control of reversible dasatinib-related pulmonary arterial hypertension and treatment-free remission of chronic myeloid leukemia: a case report. | 2022 Apr |
1 |
| 5 |
35550008 | Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells. | 2022 May 13 |
1 |
| 6 |
35551463 | BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. | 2022 May 13 |
1 |
| 7 |
33155931 | Effect of Dasatinib on Genes Related to Mitotic Catastrophe Pathway in Chronic Myeloid Leukemia Cells. | 2021 |
1 |
| 8 |
33376671 | Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1. | 2021 |
1 |
| 9 |
33390067 | In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy. | 2021 May |
1 |
| 10 |
33407162 | Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report. | 2021 Jan 6 |
1 |
| 11 |
33748144 | The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. | 2021 |
1 |
| 12 |
33772839 | High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. | 2021 Aug |
1 |
| 13 |
33814500 | BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. | 2021 Oct 1 |
2 |
| 14 |
33976882 | Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review. | 2021 Jun |
1 |
| 15 |
34054462 | A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib. | 2021 Jan-Apr |
2 |
| 16 |
34195988 | Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. | 2021 Jul |
1 |
| 17 |
34276365 | Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. | 2021 |
1 |
| 18 |
34433624 | KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia. | 2021 Aug 25 |
1 |
| 19 |
34599372 | Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein. | 2021 Oct 1 |
1 |
| 20 |
34830455 | Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors. | 2021 Nov 22 |
1 |
| 21 |
31688632 | Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature. | 2020 Oct |
1 |
| 22 |
32094501 | Innate T-αβ lymphocytes as new immunological components of anti-tumoral "off-target" effects of the tyrosine kinase inhibitor dasatinib. | 2020 Feb 24 |
1 |
| 23 |
32248338 | Dasatinib-induced chylothorax: report of a case and review of the literature. | 2020 Oct |
1 |
| 24 |
32266142 | Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion. | 2020 |
1 |
| 25 |
32279331 | Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. | 2020 Jul |
1 |
| 26 |
32340449 | In Situ Study of the Drug-Target Protein Interaction in Single Living Cells by Combining Fluorescence Correlation Spectroscopy with Affinity Probes. | 2020 May 19 |
1 |
| 27 |
32424388 | Is breaking of a hydrogen bond enough to lead to drug resistance? | 2020 Jun 18 |
1 |
| 28 |
32536651 | Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib. | 2020 Sep 15 |
2 |
| 29 |
32568522 | A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL. | 2020 Jul 17 |
4 |
| 30 |
32654459 | [Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia]. | 2020 Jun 14 |
3 |
| 31 |
32667912 | Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. | 2020 Jul |
1 |
| 32 |
32879093 | Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation. | 2020 Jul 28 |
2 |
| 33 |
33074527 | Precision medicine in acute lymphoblastic leukemia. | 2020 Dec |
1 |
| 34 |
33291786 | Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer. | 2020 Dec 4 |
1 |
| 35 |
30093398 | Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. | 2019 Jan |
1 |
| 36 |
30332954 | Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance. | 2019 |
1 |
| 37 |
30546081 | Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. | 2019 Jun |
1 |
| 38 |
30568173 | Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. | 2019 Jun |
2 |
| 39 |
30879266 | Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation. | 2019 Jul |
1 |
| 40 |
30956968 | Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib. | 2019 Mar |
1 |
| 41 |
30971653 | [The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells]. | 2019 |
1 |
| 42 |
31014138 | Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1. | 2019 Nov |
1 |
| 43 |
31539241 | Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. | 2019 Oct 24 |
1 |
| 44 |
28554234 | Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes. | 2018 Jan |
1 |
| 45 |
29035389 | 'MCC' protein interacts with E-cadherin and β-catenin strengthening cell-cell adhesion of HCT116 colon cancer cells. | 2018 Feb 1 |
1 |
| 46 |
29315500 | Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). | 2018 Apr 1 |
1 |
| 47 |
29336809 | Screening of break point cluster region Abelson tyrosine kinase inhibitors by capillary electrophoresis. | 2018 Feb 16 |
1 |
| 48 |
29434033 | PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. | 2018 May 17 |
1 |
| 49 |
29464092 | mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL. | 2018 Jan 19 |
3 |
| 50 |
29541231 | Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia. | 2018 Apr |
1 |